OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Recruiting · NCT05333328 · Interventional (participants receive a specific treatment) · Lead sponsor: Gangnam Severance Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Ovarian function suppression with endocrine treatments
What this trial is about
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
Who can take part
Age range
20 Years to 50 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- ER+HER2- breast cancer
- Premenopausal and age \<=50
- T1 or T2
- N1 including micrometastasis
- Genomic Low Risk by OncoFREE test® (1-20)
Exclusion criteria
- Postmenopausal women
- ER-negative breast cancer
Where it is running
2 locations listed.
- Seoul National University Hospital - Seoul, South Korea
- Gangnam Severance Hospital - Seoul, Korea, South Korea